Computerized facial and acoustic analysis during speech as a measurement of negative symptoms in schizophrenia

Dr. Anzalee Khan’s team is investigating an artificial intelligence (AI) enabled vocal and facial analysis, avatar driven software (called Neurological and Mental health Screening Instrument or NEMSI) to show good reliability and validity compared to existing clinician-administered psychiatric interview assessments, like: the Brief Negative Symptom Scale (BNSS), Positive and Negative Syndrome Scale (PANSS) Marder Negative Factor, and the Calgary Depression Scale (CDSS).

Study Length

One week

Disorder/Condition

Schizophrenia

Inclusion Criteria

  • Inpatients with DSM-5 diagnosis of schizophrenia
  • English-speaking
  • WRAT-4 reading ≥ 8th grade level
  • 18-60 years of age
  • Have negative symptoms: which includes diminished vocal expression, decreased or increased vocal production, and difference in intonations when speaking                                                                                                                                                                                                                                                                                                                                                                                          

Study Title (brief)

Computerized facial and acoustic analysis during speech as a measurement of negative symptoms in schizophrenia

Study Description (brief)

Dr. Anzalee Khan’s team is investigating an artificial intelligence (AI) enabled vocal and facial analysis, avatar driven software (called Neurological and Mental health Screening Instrument or NEMSI) to show good reliability and validity compared to existing clinician-administered psychiatric interview assessments, like: the Brief Negative Symptom Scale (BNSS), Positive and Negative Syndrome Scale (PANSS) Marder Negative Factor, and the Calgary Depression Scale (CDSS).

Study Contact

For more information about this study, please contact Danyah Nadim, MD, research coordinator, at 646-672-6767 or Danyah.Nadim@omh.ny.gov.

Exclusion Criteria

  • Have another DSM-5 diagnosis such as schizoaffective disorder, bipolar disorder, major depressive disorder, or tardive dyskinesia that is moderate to severe or requires treatment
  • Significant medical and/or major neurologic disorder
  • Clinically relevant abnormal movement disorders

Study Location

Manhattan Psychiatric Center, Ward's Island Complex, NY